10-QPeriod: Q1 FY2002

PROCTER & GAMBLE Co Quarterly Report for Q1 Ended Sep 30, 2001

Filed October 30, 2001For Securities:PG

Summary

Procter & Gamble (PG) reported its first quarter results for fiscal year 2001, ending September 30, 2001. Net sales decreased slightly to $9.77 billion from $9.97 billion in the prior year period. Net earnings were $1.10 billion, or $0.79 per diluted share, down from $1.16 billion, or $0.82 per diluted share, in the prior year. This decline was largely impacted by a $238 million after-tax restructuring charge related to the company's "Organization 2005" initiative. Excluding restructuring charges and prior period goodwill amortization, "core" net earnings were $1.34 billion, or $0.96 per diluted share, demonstrating underlying operational strength. The company saw significant growth in its Health Care segment, driven by oral care, pet nutrition, and pharmaceuticals, with notable contributions from the Spinbrush and Whitestrips products. The adoption of new accounting standards (SFAS No. 141 and 142) starting July 1, 2001, eliminated goodwill amortization, positively impacting future earnings and shifting the focus to annual impairment testing.

Key Highlights

  • 1Net sales for the quarter were $9.77 billion, a slight decrease from $9.97 billion in the prior year, impacted by foreign exchange and divestitures in certain segments.
  • 2Net earnings were $1.10 billion ($0.79 per diluted share), down from $1.16 billion ($0.82 per diluted share) due to a significant $238 million after-tax restructuring charge.
  • 3Excluding restructuring charges and prior period goodwill amortization, core net earnings were $1.34 billion ($0.96 per diluted share), indicating strong underlying performance.
  • 4The Health Care segment showed robust growth, with net sales up 21% and net earnings up 73%, driven by oral care, pet nutrition, and pharmaceuticals, including new product contributions like Spinbrush and Whitestrips.
  • 5Effective July 1, 2001, PG adopted SFAS No. 141 and 142, eliminating goodwill amortization and shifting to annual impairment testing, which will positively impact future reported earnings.
  • 6Cash flow from operations remained strong at $1.3 billion, an increase from $1.1 billion in the prior year, driven by improvements in working capital.
  • 7The company is actively managing its portfolio, with divestitures impacting some segments (e.g., Fabric & Home Care, Beauty Care) while others show strong growth (e.g., Health Care).

Frequently Asked Questions

The primary reason for the decrease in net earnings to $1.10 billion from $1.16 billion in the prior year is a significant $238 million after-tax restructuring charge related to the company's 'Organization 2005' initiative. This charge impacted the reported earnings for the quarter.

Effective July 1, 2001, Procter & Gamble adopted SFAS No. 141 and 142, which eliminates the amortization of goodwill and certain intangible assets. This change means that goodwill is now tested for impairment annually rather than being amortized. This accounting change positively impacts current and future reported net earnings by removing prior amortization expenses, which amounted to $53 million after-tax in the prior year period.

The Health Care segment demonstrated exceptional performance, with net sales increasing by 21% and net earnings by 73%. This growth was fueled by strong results in oral care, Iams pet health, and pharmaceuticals, with significant contributions from new products like Spinbrush and Whitestrips. The Baby, Feminine and Family Care segment also saw earnings growth, driven by family care products and strength in baby wipes.

The company is actively executing its 'Organization 2005' restructuring program, which aims to streamline operations and reduce overhead. In this quarter, $310 million before tax ($238 million after tax) was recorded for restructuring charges. While these charges negatively impact reported earnings in the short term, they are expected to yield cost savings and improve efficiency in the long run. The company continues to monitor and manage these costs as part of its strategic realignment.